Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Role of socioeconomic deprivation on inequities in care outcomes of haematological malignancies treated with stem cell transplant in the UK: a systematic review protocol.

BMJ open·2026

Same author

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026

Same author

Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors.

The Cochrane database of systematic reviews·2026

Same author

Convalescent plasma for people with COVID-19.

The Cochrane database of systematic reviews·2026

Same author

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Critical care medicine·2026

Same author

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2026

Search research articles

Related Experiment Video

Updated: May 12, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Pathogen-reduced platelets for the prevention of bleeding.

Caroline Butler¹, Carolyn Doree, Lise J Estcourt

¹Haematology Department, Oxford Radcliffe Hospital NHS Trust, Maidenhead, UK.

The Cochrane Database of Systematic Reviews

|April 2, 2013

Summary

Pathogen-reduced platelets show no difference in mortality or bleeding risk compared to standard platelets. However, standard platelets may offer benefits in certain laboratory outcomes, warranting further research.

More Related Videos

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Related Experiment Videos

Last Updated: May 12, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Area of Science:

Hematology
Transfusion Medicine
Infectious Disease Control

Background:

Platelet transfusions are crucial for managing bleeding in thrombocytopenic patients.
Despite safety measures, a risk of transfusion-transmitted infections (TTIs) persists.
Photochemical pathogen reduction aims to mitigate TTI risks and potentially extend platelet shelf-life.

Purpose of the Study:

To evaluate the effectiveness of pathogen-reduced platelets versus standard platelets in preventing bleeding.
To assess the safety and efficacy of pathogen-reduced platelet transfusions.

Main Methods:

A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.
Searched multiple databases including CENTRAL, MEDLINE, EMBASE, CINAHL, and Transfusion Evidence Library.
Included 10 RCTs comparing pathogen-reduced platelets (Intercept® and Mirasol®) with standard platelets, analyzing data from 1422 participants.

Main Results:

No significant differences were found in mortality, 'clinically significant bleeding,' or 'severe bleeding' between pathogen-reduced and standard platelets.
Pathogen-reduced platelets were associated with a higher risk of platelet refractoriness and required more frequent transfusions.
Laboratory outcomes, such as 24-hour corrected count increments, were generally inferior for pathogen-reduced platelets compared to standard platelets.

Conclusions:

Current evidence suggests no difference in major clinical outcomes like mortality and bleeding between pathogen-reduced and standard platelets.
Standard platelets demonstrated advantages in several laboratory-based efficacy measures.
Further trials with standardized outcome assessment are needed to clarify clinical differences in bleeding risk.